Important Safety Information for PT-141

Important Safety Information for PT-141

Overview: PT-141 (Bremelanotide) is a synthetic peptide that activates melanocortin receptors to enhance sexual desire and arousal. It is used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women and may be prescribed off-label for sexual wellness in both men and women.

General Safety Information

PT-141 is generally well tolerated when used as directed. Most side effects are mild and temporary, resolving without medical intervention. However, individual responses may vary, and regular monitoring is recommended during treatment.

Common Side Effects

  • Nausea (most common, especially after initial doses)
  • Flushing or warmth in the face and chest
  • Headache
  • Injection site reactions: pain, redness, swelling, or itching
  • Fatigue or drowsiness

Less Common Side Effects

Some individuals may experience:

  • Vomiting
  • Nasal congestion
  • Dizziness or lightheadedness
  • Changes in blood pressure (temporary increase)
  • Darkening of skin or gums (hyperpigmentation) with prolonged use
  • Decreased appetite

If any of these symptoms persist or worsen, contact your healthcare provider.

Serious Risks and Warnings

PT-141 may temporarily affect cardiovascular function.

  • Blood pressure monitoring is recommended, especially for individuals with a history of hypertension or cardiovascular conditions
  • Use caution in patients with uncontrolled high blood pressure or cardiovascular disease
  • Darkening of skin (hyperpigmentation) may occur with repeated use, particularly in areas of increased melanin production
  • Although rare, allergic reactions may occur. Seek immediate medical attention for symptoms such as severe rash, swelling, difficulty breathing, or chest pain

Contraindications

PT-141 should not be used in the following cases:

  • Known hypersensitivity to PT-141 (Bremelanotide) or its components
  • Uncontrolled hypertension or cardiovascular disease
  • Pregnancy or plans to become pregnant
  • Breastfeeding
  • Concurrent use with medications for erectile dysfunction (e.g., sildenafil, tadalafil) without medical supervision

Drug Interactions

PT-141 may interact with:

  • Blood pressure medications, which may result in additive effects on blood pressure
  • Other medications affecting melanocortin pathways
  • Alcohol, which may increase the risk of dizziness or low blood pressure

Always inform your healthcare provider of all medications, supplements, and herbal products you are taking.

Pregnancy and Breastfeeding

PT-141 is not recommended during pregnancy or while breastfeeding. Its safety in these populations has not been established. Effective contraception should be used during treatment unless otherwise directed by your provider.

Storage Instructions

  • Injection form: Store refrigerated at 2–8°C (36–46°F). Do not freeze. Protect from light.
  • Once reconstituted, use within the timeframe specified by your provider (typically 30 days when refrigerated)

Keep out of reach of children. Do not use after the expiration date printed on the packaging.

Usage Guidelines

  • PT-141 is typically administered subcutaneously at least 45 minutes before anticipated sexual activity
  • Do not exceed recommended dosing frequency (typically no more than 8 doses per month)
  • Effects may be noticed within 2-4 hours and can last up to 24 hours
  • Nausea is most common with initial doses and often decreases with continued use

Consultation

For questions regarding dosing, side effects, or treatment options, consult your healthcare provider.

Disclaimer

This information is intended for educational purposes only and does not substitute professional medical advice. The product has not been evaluated by the Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease.